>
Switch to:

Orgenesis EBIT

: $-17.01 Mil (TTM As of Dec. 2021)
View and export this data going back to 2010. Start your Free Trial

Orgenesis's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2021 was $-4.81 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2021 was $-17.01 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Orgenesis's annualized ROC % for the quarter that ended in Dec. 2021 was -41.75%. Orgenesis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -107.69%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Orgenesis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -29.45%.

Orgenesis EBIT Historical Data

The historical data trend for Orgenesis's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21
EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.44 -15.01 -22.32 -95.48 -17.01

Orgenesis Quarterly Data
Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.72 0.09 -2.45 -9.83 -4.81

Orgenesis EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis  (NAS:ORGS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Orgenesis's annualized ROC % for the quarter that ended in Dec. 2021 is calculated as:

ROC % (Q: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2021 ) + Invested Capital (Q: Dec. 2021 ))/ count )
=-18.512 * ( 1 - -0.86% )/( (42.764 + 46.684)/ 2 )
=-18.6712032/44.724
=-41.75 %

where

Invested Capital(Q: Sep. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=65.204 - 7.523 - ( 14.917 - max(0, 13.566 - 36.341+14.917))
=42.764

Invested Capital(Q: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=59.841 - 7.684 - ( 5.473 - max(0, 15.365 - 25.758+5.473))
=46.684

Note: The Operating Income data used here is four times the quarterly (Dec. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Orgenesis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2021  Q: Dec. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-19.24/( ( (6.828 + max(9.547, 0)) + (11.286 + max(8.071, 0)) )/ 2 )
=-19.24/( ( 16.375 + 19.357 )/ 2 )
=-19.24/17.866
=-107.69 %

where Working Capital is:

Working Capital(Q: Sep. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.95 + 0.133 + 2.154) - (7.523 + 1.167 + 0)
=9.547

Working Capital(Q: Dec. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.245 + 0.118 + 1.689) - (7.684 + 1.297 + -1.7763568394003E-15)
=8.071

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2021) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Orgenesis's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2021 )
=-17.008/57.746
=-29.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis EBIT Related Terms

Thank you for viewing the detailed overview of Orgenesis's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Comparable Companies
NAS:CASI ROCO:6461 NAS:PRTG XKRX:291650 NAS:ENTX TSE:4588 OSTO:ACE NAS:EYEN TSX:ONC XKRX:072520
Traded in Other Exchanges
45O:Germany 45O:Germany
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Website
https://www.orgenesis.com
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

From GuruFocus

Orgenesis and Theracell Joint Venture to Receive up to €32 Million From Greek Government to Accelerate Rollout of POCare Centers and Deployment of OMPULs

By GuruFocusNews 11-29-2021

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2® to Treat ARDS Resulting from COVID-19 Infection

By Marketwired 05-06-2021

Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis' Proprietary POCare Technologies for the Generation and Expansion of T-Cells

By Marketwired 07-14-2020

Orgenesis Schedules Fiscal 2020 Year-End Business Update Conference Call

By Marketwired 03-04-2021

Orgenesis CEO to Participate in Webinar Panel on "New Approaches to COVID-19" on Thursday, September 10th

By Marketwired 09-09-2020

Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase for the Treatment of External Genital Warts

By Marketwired 08-20-2020

Orgenesis Inc. Announces $14.8 Million Private Placement

By GuruFocusNews 03-31-2022

Orgenesis Stock Appears To Be Modestly Overvalued

By 06-23-2021

Orgenesis Announces Virtual 2020 Annual Meeting of Stockholders

By Marketwired 11-03-2020

Orgenesis Schedules 2021 Fiscal Year Business Update Conference Call

By GuruFocusNews 03-29-2022

Other Sources

$ORGS - Orgenesis: A Mispriced Visionary In Cell And Gene Therapy Manufacturing. Orgenesis A Mispriced Biotech Visionary

By Seekingalpha 2021-05-17

$ORGS - Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2021-11-06

$ORGS - Orgenesis: A Cell And Gene Therapy Disruptor With A Nice Risk Reward Profile. Orgenesis Cell And Gene Therapy Disruptor Nice Risk Reward Profile

By Seekingalpha 2021-01-28

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)